期刊文献+

TPSA、FPSA/TPSA及PSAD在前列腺癌诊断中作用的比较研究

Significance of TPSA, FPSA/TPSA and PSAD in diagnosis of prostatic cancer: a comparative study
在线阅读 下载PDF
导出
摘要 目的比较TPSA、FPSA/TPSA及PSAD在前列腺癌诊断中的作用价值。方法回顾性研究经病理确诊的前列腺癌患者61例和前列腺增生患者74例的临床资料,计算F/T值和PSAD值。统计分析两组间各指标的差异性。计算三项指标不同取值时诊断前列腺癌的敏感度和特异度,比较其在前列腺癌诊断中的价值。结果前列腺癌(PCA)组与前列腺增生(BPH)组之间TPSA、FPSA/TPSA及PSAD的差异均有统计学意义。TPSA截点为4ng/ml和10ng/ml时的敏感度分别为98.36%和86.88%,特异度为55.05%和69.74%。F/T截点为0.1、0.15和0.20时的敏感度分别为38.64%、70.45%和81.82%,特异度为60.71%、58.49%、49.31%。PSAD截点为0.1、0.15和0.20时的敏感度为98.36%、93.44%、85.25%,特异度为67.41%、69.51%、81.25%。结论TPSA和PSAD在诊断前列腺癌时的敏感度相近,但PSAD的特异度优于TPSA。F/T作为单独指标诊断前列腺癌的价值不大,但作为TPSA的辅助指标能提高诊断的特异度。 Objective To compare the value of TPSA, FPSA/TPSA and PSAD for the diagnosis of prostatic cancer (PCa). Methods Data of 61 patients with PCa and 74 patients with BPH were reviewed retrospectively. The differences of TPSA, FPSA/TPSA and PSAD between the two groups were analyzed, and the sensitivity and specificity of them in diagnosing PCa were compared. Results TPSA, FPSA/TPSA and PSAD were significantly different between PCa and BPH groups. At the shear point of 4 ng/ml and 10 ng/ml, the sensitivity of TPSA was 98.36% and 86.88%, and the specificity was 55.05% and 69.74%, respectively. At the shear point of 0.1, 0.15 and 0.20, the sensitivity of F/T was 38.64%, 70.45% and 81.82%, and the specificity was 60.71%, 58.49% and 49.31%. respeclively. At the shear point of 0.1, 0.15 and 0.20, the sensitivity of PSAD was 98.36%, 93.44% and 85.25%, and the specificity was 67.41%, 69.51% and 81.25%, respectively. Conclusions PSAD is more reliable than TPSA and F/T for diagnosing PCa.
出处 《老年医学与保健》 CAS 2007年第3期160-162,共3页 Geriatrics & Health Care
关键词 前列腺特异性抗原 前列腺肿瘤 敏感性与特异性 Prostate-specific antigen: Prostetic neoplasms Sensitivity and specificity
  • 相关文献

参考文献7

  • 1施国伟,何家扬.前列腺检查对PSA、fPSA的影响研究[J].国外医学(泌尿系统分册),2001,21(2):73-74. 被引量:1
  • 2Reiter W,Stieber P,Schmeller N.The ratio of free to total prostate specific antigen:an advantageous addition in the differential diagnosis of benign hyperplasia and cancer of the prostate ?Anticancer Res,1997,17(4B):2987~2991.
  • 3Higashihara E,Nutahara K,Kojima M,et al.Significance of serom free prostate specific antigen in the screening of prostate cancer.J Urol,1996,156:1964~1968.
  • 4Weckermann D,Maassen C,Wawroschek F,et al.Improved discrimination of prostate cancer and benign prostatic hyperplasia by means of the quotient of free and total PSA.Int Urol Nephrol,1999,31:351~359.
  • 5Stephan C,Stroebel G,Heinau M,et al.The ratio of prostatespecific antigen (PSA) to prostate volume (PSA density) as a parameter to improve the detection of prostate carcinoma in PSA values in the range of< 4 ng/mL.Cancer,2005,104:993~1003.
  • 6Brassell SA,Kao TC,Sun L,et al.Prostate-specific antigen versus prostate-specific antigen density as predictor of tumor volume,margin status,pathologic stage,and biochemical recurrence of prostate cancer.Urology,2005,66:1229~1233.
  • 7林延双,梁建波,何大光,玉海,韦华玉,蓝志相.TPSAF/T比值PSAD在早期前列腺癌诊断作用中的比较研究[J].临床泌尿外科杂志,2006,21(11):852-854. 被引量:7

二级参考文献8

  • 1常江平.前列腺增生体积和患者年龄对PSA的影响[J].临床泌尿外科杂志,1996,11(4):207-209. 被引量:10
  • 2Stenman U H, Leininen J, Alfthan H, et al. A complex between prostate specific antigen and alpha 1-antichy-motrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer [J].Cancer-Res, 1991,51 ( 1 ) :222-226.
  • 3Higashihara E, Nutahara K, Kojima M, et al. Significance of serum free prostate specific antigen in the screening of prostate cancer[J]. J Urol,1996,156(6):1964-1968.
  • 4Stephan C, Lein M, Jung K, et al. The influence of prostate volume on the ratio of free to total prostate specific antigen in serum of patients with prostate carcinoma and benigh prostate hyperplasia[J]. Cancer,1997,79(1) :104-109.
  • 5Catalona W J, Smith D S,Wolfert R L,et al. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening[J]. JAMA,1995,274(15):1214-1220.
  • 6Benson M C, Whang L S, Pantuek A, et al. prostate specific antigen density: a means of distinguishing benign prostatic by pertrophy and prostate cancer[J]. J Urol,1992, 147(3PTZ) :815-816.
  • 7Semjonow A, Hamm M, Rathert P. The quotient of prostate-specific antigen and prostate volume. Improved differentiation between benign prostatic hyperplasia and locally circumscribed prostate cancer[J]. Urologe, 1993,32(3) :250-253.
  • 8Stamey T A, Kabalin J N, Ferrari M, et al, Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. IV. Anti-androgen treated patients[J]. J Urol,1989,141(5):1088-1090.

共引文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部